CNTA
insider transactionsCentessa Pharmaceuticals plc — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-493.1K
0 buy · 493.1K sell
Net value · 365d
-$13.3M
$0 in · $13.3M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
12
0 buy · 493.1K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
Chief Executive Officer
$23.8K
604 sh · $39.42
Own -0%
-
Exercise·M
Chief Business Officer · 10b5-1
$0
24.0K sh
Own +343%
-
Sell·S
Chief Business Officer · 10b5-1
$719.9K
24.0K sh · $30.00
Own -27%
-
Exercise·M
Chief Business Officer · 10b5-1
$92.4K
24.0K sh · $3.85
Own +36%
-
Exercise·M
Chief People Officer · 10b5-1
$0
41.1K sh
Own +96%
-
Sell·S
Chief People Officer · 10b5-1
$1.2M
41.1K sh · $30.12
Own -40%
-
Exercise·M
Chief People Officer · 10b5-1
$329.0K
41.1K sh · $8.01
Own +66%
-
Exercise·M
Chief People Officer · 10b5-1
$0
10.0K sh
Own +15%
-
Sell·S
Chief People Officer · 10b5-1
$282.2K
10.0K sh · $28.10
Own -14%
-
Exercise·M
Chief People Officer · 10b5-1
$40.3K
10.0K sh · $4.01
Own +16%
-
Exercise·M
Chief People Officer · 10b5-1
$0
64.8K sh
Own +319%
-
Sell·S
Chief People Officer · 10b5-1
$1.8M
64.8K sh · $28.21
Own -51%
-
Exercise·M
Chief People Officer · 10b5-1
$259.7K
64.8K sh · $4.01
Own +104%
-
Sell·S
Chief Business Officer · 10b5-1
$324.3K
11.9K sh · $27.16
Own -15%
-
Sell·S
Chief Business Officer · 10b5-1
$1.6M
61.3K sh · $26.17
Own -44%
-
Exercise·M
Chief People Officer · 10b5-1
$0
109.4K sh
Own +433%
-
Sell·S
Chief People Officer · 10b5-1
$327.4K
12.1K sh · $27.13
Own -16%
-
Sell·S
Chief People Officer · 10b5-1
$2.8M
108.0K sh · $26.15
Own -59%
-
Exercise·M
Chief People Officer · 10b5-1
$438.7K
109.4K sh · $4.01
Own +150%
-
Exercise·M
Chief People Officer · 10b5-1
$0
15.2K sh
Own +115%
-
Exercise·M
Chief People Officer · 10b5-1
$0
94.2K sh
Own +170%
-
Sell·S
Chief People Officer · 10b5-1
$327.4K
12.1K sh · $27.13
Own -16%
-
Sell·S
Chief People Officer · 10b5-1
$2.8M
108.0K sh · $26.15
Own -59%
-
Exercise·M
Chief People Officer · 10b5-1
$58.4K
15.2K sh · $3.85
Own +9%
-
Exercise·M
Chief People Officer · 10b5-1
$377.8K
94.2K sh · $4.01
Own +130%
-
Grant·A
Chief Medical Officer
$0
120.0K sh
Own New
-
Grant·A
John J Crowley KEY
Chief Financial Officer
$0
181.0K sh
Own New
-
Grant·A
John J Crowley KEY
Chief Financial Officer
$0
45.0K sh
Own New
-
Grant·A
Chief Accounting Officer
$0
42.0K sh
Own New
-
Grant·A
Chief Accounting Officer
$0
11.0K sh
Own New
-
Grant·A
Chief Legal Officer
$0
160.0K sh
Own New
-
Grant·A
Chief Legal Officer
$0
20.0K sh
Own +20%
-
Grant·A
Chief Legal Officer
$0
40.0K sh
Own +69%
-
Sell·S
Chief Legal Officer
$979.7K
39.0K sh · $25.15
Own -40%
-
Grant·A
Chief Business Officer
$0
123.0K sh
Own New
-
Grant·A
Chief Business Officer
$0
31.0K sh
Own +29%
-
Grant·A
Chief Technology & Quality Ofc
$0
140.0K sh
Own New
-
Grant·A
Chief Technology & Quality Ofc
$0
35.0K sh
Own +31%
-
Grant·A
Chief People Officer
$0
117.0K sh
Own New
-
Grant·A
Chief People Officer
$0
29.0K sh
Own +66%
-
Grant·A
Chief Executive Officer
$0
273.0K sh
Own New
-
Grant·A
Chief Executive Officer
$0
68.0K sh
Own +39%
-
Other·F
Chief Legal Officer
$191.2K
7.8K sh · $24.57
Own -7%
-
Other·F
Chief Business Officer
$347.9K
14.2K sh · $24.57
Own -12%
-
Other·F
Chief Technology & Quality Ofc
$210.0K
8.5K sh · $24.57
Own -7%
-
Other·F
Chief People Officer
$260.6K
10.6K sh · $24.57
Own -20%
-
Other·F
Chief Executive Officer
$71.6K
2.9K sh · $24.57
Own -2%
-
Sell·S
Chief Legal Officer
$25.3K
1.0K sh · $25.01
Own -1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 1, 2026 | Mario Alberto Accardi KEY | Other F | 604 | $23.8K |
| Mar 26, 2026 | Gregory M Weinhoff 10b5-1 | Exercise M | 24.0K | $0 |
| Mar 26, 2026 | Gregory M Weinhoff 10b5-1 | Sell S | 24.0K | $719.9K |
| Mar 26, 2026 | Gregory M Weinhoff 10b5-1 | Exercise M | 24.0K | $92.4K |
| Mar 26, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 41.1K | $0 |
| Mar 26, 2026 | Karen M. Anderson 10b5-1 | Sell S | 41.1K | $1.2M |
| Mar 26, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 41.1K | $329.0K |
| Mar 17, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 10.0K | $0 |
| Mar 17, 2026 | Karen M. Anderson 10b5-1 | Sell S | 10.0K | $282.2K |
| Mar 17, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 10.0K | $40.3K |
| Mar 16, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 64.8K | $0 |
| Mar 16, 2026 | Karen M. Anderson 10b5-1 | Sell S | 64.8K | $1.8M |
| Mar 16, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 64.8K | $259.7K |
| Mar 13, 2026 | Gregory M Weinhoff 10b5-1 | Sell S | 11.9K | $324.3K |
| Mar 13, 2026 | Gregory M Weinhoff 10b5-1 | Sell S | 61.3K | $1.6M |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 109.4K | $0 |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Sell S | 12.1K | $327.4K |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Sell S | 108.0K | $2.8M |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 109.4K | $438.7K |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 15.2K | $0 |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 94.2K | $0 |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Sell S | 12.1K | $327.4K |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Sell S | 108.0K | $2.8M |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 15.2K | $58.4K |
| Mar 13, 2026 | Karen M. Anderson 10b5-1 | Exercise M | 94.2K | $377.8K |
| Feb 2, 2026 | Stephen Kanes | Grant A | 120.0K | $0 |
| Feb 2, 2026 | John J Crowley KEY | Grant A | 181.0K | $0 |
| Feb 2, 2026 | John J Crowley KEY | Grant A | 45.0K | $0 |
| Feb 2, 2026 | Raphael Deferiere | Grant A | 42.0K | $0 |
| Feb 2, 2026 | Raphael Deferiere | Grant A | 11.0K | $0 |
| Feb 2, 2026 | Iqbal J Hussain | Grant A | 160.0K | $0 |
| Feb 2, 2026 | Iqbal J Hussain | Grant A | 20.0K | $0 |
| Feb 2, 2026 | Iqbal J Hussain | Grant A | 40.0K | $0 |
| Feb 2, 2026 | Iqbal J Hussain | Sell S | 39.0K | $979.7K |
| Feb 2, 2026 | Gregory M Weinhoff | Grant A | 123.0K | $0 |
| Feb 2, 2026 | Gregory M Weinhoff | Grant A | 31.0K | $0 |
| Feb 2, 2026 | Tia L Bush | Grant A | 140.0K | $0 |
| Feb 2, 2026 | Tia L Bush | Grant A | 35.0K | $0 |
| Feb 2, 2026 | Karen M. Anderson | Grant A | 117.0K | $0 |
| Feb 2, 2026 | Karen M. Anderson | Grant A | 29.0K | $0 |
| Feb 2, 2026 | Mario Alberto Accardi KEY | Grant A | 273.0K | $0 |
| Feb 2, 2026 | Mario Alberto Accardi KEY | Grant A | 68.0K | $0 |
| Feb 1, 2026 | Iqbal J Hussain | Other F | 7.8K | $191.2K |
| Feb 1, 2026 | Gregory M Weinhoff | Other F | 14.2K | $347.9K |
| Feb 1, 2026 | Tia L Bush | Other F | 8.5K | $210.0K |
| Feb 1, 2026 | Karen M. Anderson | Other F | 10.6K | $260.6K |
| Feb 1, 2026 | Mario Alberto Accardi KEY | Other F | 2.9K | $71.6K |
| Jan 30, 2026 | Iqbal J Hussain | Sell S | 1.0K | $25.3K |
About CNTA insider trading
This page tracks insider transactions for Centessa Pharmaceuticals plc (CNTA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.